Overview

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Status:
Not yet recruiting
Trial end date:
2024-03-15
Target enrollment:
Participant gender:
Summary
This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Bioray Laboratories
Collaborators:
Institute of Hematology ＆ Blood Diseases Hospital，Chinese Academy of Medical Sciences
Wuhan Union Hospital, China
Zhejiang University